Immunotherapy of lung cancer using biotechnological methods.

为评价白细胞介素2(IL2)和淋巴因子激活的杀伤细胞(LAK细胞)过继免疫治疗联合化疗或放疗治疗晚期非小细胞肺癌(NSCLC)的疗效，进行了一项随机对照研究。对1985年1月至1990年12月在本院行原发灶切除的403例非小细胞肺癌患者中，106例相对根治性切除和非根治性切除的患者进入术后辅助免疫治疗的随机对照试验。前者分为3组：a化疗组(CDDP+VDS)(n=13)，b)化疗(CDDP+VDS+IL2+LAK细胞)组(n=12)，c)对照组(n=11)。未治愈组(n=68)随机分为免疫治疗(化疗/放疗+IL2+LAK细胞)组(n=33)和对照组(单纯化疗/放疗)(n=35)，免疫治疗(b+d)组和对照组(a+c+e)总的4年生存率分别为52.4%和28.3%，经广义Wilcoxon检验，差异有统计学意义(p&lt；0.01)。在相对治愈组中，a)、b、c)组的4年生存率分别为34.2%、70.9%和34.1%。在非治愈组中，d)组和e)组分别为43.1%和29.3%(p&lt；0.05)。提示IL-2联合LAK细胞过继免疫治疗是晚期非小细胞肺癌患者术后有效的辅助免疫治疗方法。

A controlled, randomized study has been conducted to assess the efficacy of adoptive immunotherapy with Interleukin 2(IL2)and lymphokine activated killer cells(LAK cells)combined with chemotherapy or radiotherapy for advanced non-small cell lung cancer(NSCLC)patients. Out of 403 NSCLC patients who received resection of primary tumors from Jan. 1985 to Dec. 1990 in our hospital, a total of 106 patients with relatively curative and non-curative resection, were entered into a randomized controlled trial of postoperative adjuvant immunotherapy. The former group(n=36)was divided into three groups ; a)Chemotherapy(CDDP+VDS)group(n=13), b)Chemoimmunotherapy(CDDP+VDS+IL2+LAK cells)group(n=12), and c)control group(n=ll). The latter(noncurative)group(n=68)was randomized into d)immunotherapy(chemo/radiotherapy+IL2+LAK cells)group(n=33)and e)control(chemo/radiotherapy alone)group(n=35).The overall 4 year survival rates of immunotherapy(b+d)and control(a+c+e)groups were 52.4% and 28.3% respectively and the difference was significant(p<0.01)with generalized Wilcoxon test. In the relative curative group, the 4 year survival rates of a), b), and c)groups were 34.2%, 70.9% and 34.1% respectively. In the non-curative group, those of d)and e)groups were 43.1% and 29.3%(p<0.05). From this study, it it suggested that adoptive immunotherapy with IL2 and LAK cells is effective as a postoperative adjuvant immunotherapy for advanced NSCLC patients.